Gen. Pharmac. Vol. 16, No. 1, pp.i-xxii , 1985 Pergamon Press Ltd. Printed in Great Britain

NEW PATENTS

This Section contains abstracts and, where appropriate, illustrations of recently issued United States patents and published patent applications filed from over 30 countries under the Patent Cooperation Treaty. This information was obtained from recent additions to the Pergamon PATSEARCH ® online database in accordance with interest profiles developed by the Editors. Further information about Pergamon PATSEARCH ® can be obtained from Pergamon InfoLine Inc., 1340 Old Chain Bridge Road, McLean, Virginia 22101 U.S.A.

Copies of complete patents announced in this Section are available from Pergamon InfoLine Inc. for $8 per copy. Payment with order is required. Orders outside North America add $2 for air postage. Order by patent number for Pergamon InfoLine only.

4145410

M E T H O D O F P R E P A R I N G A C O N T R O L L E D - R E L E A S E

P H A R M A C E U T I C A L P R E P A R A T I O N , A N D R E S U L T I N G

C O M P O S I T I O N

Barry Sears

A method of preparing a controlled-release pharmaceutical compound for Oral Adminis- tration, which pharmaceutical compound is subject to Enzymatic Hydrolysis on Oral Administration, which method comprises en- capsulating the pharmaceutical compound with a synthetic phosphatidyl compound having a Modified Polarhead Moiety which increases the resistance of the phosphatidyl compound to Phospholipase C Hydrolysis.

4440757

P H A R M A C E U T I C A L C O M P O S I T I O N C O M P R I S I N G

D E R I V A T I V E O F A M I N O B E N Z O I C A C I D F O R

R E G U L A T I N G P R O S T A G L A N D I N

Chikao Yoshikumi, Yoshio Ohmura, Fumio Hirose, Masanori Ikuzawa, Kenichi Matsunaga, Takayoshi Fujii, Minoru Ohhara, Takao Ando, Kunitachi, Japan assigned to Kureha Kagaku Kogyo Kabushiki Kaisha

COOR 2 ~ NH--R 1

A pharmaceutical composition for regulating prostagrandins, which comprises (a) a derivative

of aminobenzoic acid, represented by the fol- lowing general formula: See Patent for Chemical Structure wherein R 1 denotes one member selec- ted from the group consisting of the residual groups formed by removing OH at l(alpha)-or 1(beta) position from arabinose, xylose, rham- nose, glucose, galactose, mannose and fructose, and R2 is a hydrogen atom, an alkyl group of one to four carbon atoms or a pharmaceutically acceptable metal, and (b) a pharmaceutically ac- ceptable carrier or diluent of (a) is disclosed.

4440759

2 0 - A M I N O T Y L O S I N D E R I V A T I V E S A N D P H A R M A C E U T I C A L

C O M P O S I T I O N S C O N T A I N I N G S A M E

Satoshi Omura, Akira Nakagawa, Setagaya ku, Tokyo, Japan

0

C H ~ CH3\ //~CH2~CH2~X

" o o

CH30Q

~N N~R 12 N . . /

o.P. t6/l--F i